<DOC>
	<DOCNO>NCT00802217</DOCNO>
	<brief_summary>Safety pharmacokinetic first-time-in-human study orally administer civamide healthy subject .</brief_summary>
	<brief_title>Oral Civamide Safety , Tolerability First Human Study</brief_title>
	<detailed_description>This open-label , non-randomized pharmacokinetic study two dosage strength oral Civamide . The study consist Screening Period ( Days -21 Day -2 ) , Admittance Period , A 4 Day in-house Treatment Period ( Days 1-4 ) ) follow-up Visit Day 7 . Pharmacokinetics assess specified timepoints relative dose Day 1 in-house stay . Subjects discharge research unit follow 72 hr blood draw . Subjects return research unit Day 7 follow-up safety assessment .</detailed_description>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>1 . Subject voluntarily agree participate study sign IRBapproved inform consent prior perform screen procedure . 2 . Healthy , determine prestudy medical evaluation ( medical history physical examination , vital sign , ECG , clinical laboratory evaluation ) . 3 . Males females 18 45 year age , inclusive . 4 . Female subject must nonchildbearing potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal ≥ 1 year ) follicle stimulate hormone [ FSH ] &gt; 40 U/L ) . 5 . Nonsmokers ( nicotine use ) determine history ( nicotine use past year ) urine cotinine concentration ( &lt; 200 ng/ml ) screen and/or Day 1 . 6 . Body mass index ( BMI ) 18.5 30.5 kg/m2 , inclusive , screen . 7 . Subject willing able cooperate extent require protocol . 1 . Clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) determine Investigator designee . 2 . Subjects history clinical finding coronary artery disease/cardiovascular disease ECG finding judge clinically significant Investigator . 3 . Any disorder would interfere absorption , distribution , metabolism , excretion drug . 4 . Subjects active upper gastrointestinal problem gastroesophageal reflux disease ( GERD ) , peptic ulcer disease . 5 . Subject know allergy hypersensitivity capsicum , Civamide , capsaicincontaining product . 6 . Positive screen test Hepatitis B surface antigen , Hepatitis C antibody , HIV antibody . 7 . Subject history alcohol and/or illicit drug abuse within two year entry . 8 . Positive blood test ethanol screen Day 1 . 9 . Positive urine drug test ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , tetrahydrocannabinol [ THC ] , etc . ) screen Day 1 . 10 . Female subject childbearing potential pregnant breastfeeding . 11 . Inability refrain consumption coffee caffeine contain beverage within 24 hour prior Day 1 discharge unit Day 4 . 12 . Inability refrain use alcohol alcoholcontaining food , medication beverage within 48 hour prior Day 1 discharge unit Day 4 . 13 . Topical use capsaicincontaining product 60 day prior Day 1 end study participation . 14 . Ingestion capsaicincontaining food ( capsicum , cayenne pepper , red pepper , green pepper , Scotch Bonnet , Habanero pepper , African chilies , Tabasco pepper , paprika , pimiento , Mexican chilies , Louisiana long pepper , Louisiana short pepper , Bird pepper , Garden pepper , Goat 's pod , Grains Paradise , Hot pepper , Hungarian Pepper , Ici Fructus , Sweet pepper , Zanzibar pepper ) 48 hour Day 1 end study participation . 15 . Donation blood ( &gt; 250 ml ) blood product within 2 month ( 56 day ) prior Day 1 . 16 . Consumption grapefruit contain food/beverages Seville orange ( orange marmalade ) 7 day prior Day 1 discharge unit Day 4 . 17 . Use counter ( OTC ) medication ( include vitamin ) , prescription medication , herbal remedy 14 day prior Day 1 discharge unit Day 4 . By exception , acetaminophen £ 1 gram per day permit hormone replacement therapy permit . 18 . Use investigational drug within 30 day prior Day 1 . 19 . Unwilling abstain vigorous exercise 48 hour prior Day 1 discharge unit Day 4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>